Operator

Good morning, and welcome to the Nano Dimension and Infinite Epigenetics Investor Conference Call to discuss proposed business combination. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Purva Sanariya, Director, Investor Relations at Nano Dimension. Please go ahead.

Purva Sanariya
Director of Investor Relations

Thank you, and good morning, everyone. Welcome to Nano Dimension's and Infinite Epigenetics Investor conference call to discuss their proposed business combination and strategic rationale for creating a publicly traded AI-powered preventive health and diagnostics company. Joining me today is our Chief Executive Officer, Dave Stehlin; and Dr. Matthew Dawson, Co-Founder and Chief Executive Officer of Infinite Epigenetics.

Earlier today, Nano Dimension issued a press release announcing that it has entered into a nonbinding term sheet for a proposed business combination with Infinite Epigenetics. Nano Dimension has also posted a supplemental investor presentation to the Investor Relations section of its website, and we encourage listeners to review those materials for additional detail.

Before we begin, please note that today's discussion will include forward-looking statements within the meaning of federal securities laws, including statements regarding the proposed business combination and anticipated benefits of the transaction, the expected strategy and opportunities for the combined company, product development, clinical and commercial plans, reimbursement, market opportunity and other statements that are not historical facts.

Forward-looking statements are not guarantees and involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company to be materially different from any future results performance or achievements expressed or implied by the forward-looking statements. The safe harbor